Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to Aids

Published in:
Journal of general virology

DOI:
10.1099/0022-1317-78-8-1913

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS

Carel A. van Baalen,1 Oscar Pontesilli,2 Robin C. Huisman,1 Anna Maria Geretti,1† Michèl R. Klein,2 Frank de Wolf,3 Frank Miedema,2 Rob A. Gruters1,4 and Albert D. M. E. Osterhaus1

1 Institute of Virology, Room Ee-1726, Erasmus University Rotterdam, PO Box 1738, 3000 DR Rotterdam, The Netherlands
2 Department of Clinical Viro-Immunology, The Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, and Laboratory for Experimental and Clinical Immunology, University of Amsterdam, Amsterdam, The Netherlands
3 Department of Human Retrovirology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
4 UMR103, CNRS/Biomerieux, ENS de Lyon, Lyon, France

Immunological correlates of AIDS-free survival after human immunodeficiency virus type 1 (HIV-1) infection are largely unknown. Cytotoxic T lymphocyte (CTL) responses are generally believed to be a major component of protective immunity against viral infections. However, the relationship between HIV-1-specific CTL responses and disease progression rate is presently unclear. Here we show in twelve HIV-1-infected individuals that detection of Rev-specific CTL precursors (CTLp) early in the asymptomatic stage, as well as detection of Rev- and Tat-specific CTLp later during follow-up, inversely correlate with rapid disease progression. No such correlation was found for detection of CTLp against Gag, RT or Nef. Further studies are required to determine whether a protective mechanism is indeed the basis of the observed correlation. The data presented are in agreement with the hypothesis that CTL against proteins that are important for early viral transcription and translation are of particular importance in protection from rapid disease progression.

The duration of the asymptomatic period after human immunodeficiency virus type 1 (HIV-1) infection varies considerably (Klein & Miedema, 1995; Haynes et al., 1996), and is inversely related to plasma RNA levels following initial viraemia (Jurriaans et al., 1994; Mellors et al., 1996). These parameters may be determined by viral characteristics, host genetics and immunological factors (Klein & Miedema, 1995; Bollinger et al., 1996; Haynes et al., 1996). Cytotoxic T lymphocyte (CTL) responses are associated with initial control of viraemia, persist in asymptomatic individuals, and eventually decline with disease progression (Carmichael et al., 1993; Borrow et al., 1994; Koup et al., 1994; Klein et al., 1995; Rinaldo et al., 1995; Bollinger et al., 1996; Geretti et al., 1996). This decline coincides with HIV-1-induced CD4+ T cell loss and perturbation of T cell function (Klein et al., 1995; Geretti et al., 1996).

Recent reports on virus escape from HIV-1-specific CTL responses clearly indicate that CTL exert pressure on virus replication in vivo, but that the overall CTL efficacy may be dependent on the (lack of) conservation in the epitope sequences (Borrow et al., 1997; Goulder et al., 1997). In addition, it has been suggested that CTL responses against early expressed epitopes may be more efficacious than those against late expressed epitopes (Ranki et al., 1994; Riviere et al., 1994). Qualitative and quantitative analyses of specific CTL responses, before the immune status has deteriorated, may identify the requirements for a CTL response to be protective. In asymptomatic HIV-1-infected individuals the early expressed proteins Rev and Tat are generally less frequently recognized than the late expressed structural proteins Gag and RT (Johnson & Walker, 1994; Riviere et al., 1994; Lamhamedi-Cherradi et al., 1995).

Here, we investigated whether differences between CTL responses against HIV-1 Gag, RT, Nef, Rev and Tat are related to differences in disease progression rates. CTL precursor (CTLp) frequencies were determined in twelve participants of the Amsterdam Cohort Studies on AIDS, who were selected on the basis of their disease progression rates and HLA phenotypes (Table 1). Seven of these individuals remained AIDS-free for more than a decade (median 129 months, range 110–140) after seroconversion (L090, L658, L709 and L434) or
Table 1. Characteristics of the seven LTA and five progressors selected for this study

<table>
<thead>
<tr>
<th>Individual*</th>
<th>HLA phenotype</th>
<th>Serostatus interval (months)</th>
<th>AIDS</th>
<th>CD4 &lt; 200†</th>
<th>Asymptomatic Follow-up</th>
<th>CD4 slope (cells/µl per month)</th>
<th>Virus load‡</th>
<th>Sampling for CTL assays (months after seroconversion CD4 cell count (cells/µl))</th>
</tr>
</thead>
<tbody>
<tr>
<td>L090</td>
<td>A 1,2 41.57, B I 2.6</td>
<td>NA NA &gt; 129 + 1.1 &lt; 10³</td>
<td>24</td>
<td>860</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>L658</td>
<td>A 1,2 8.61, B I 3.3</td>
<td>NA NA &gt; 110 - 1.5 8.3 x 10³</td>
<td>4</td>
<td>950</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>L211</td>
<td>A 1,2 8.57, B II NA NA &gt; 139 - 3.1 NT</td>
<td>24</td>
<td>730</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>L709</td>
<td>A 1,2 14.57, B I 3.4</td>
<td>NA NA &gt; 122 - 3.5 2.5 x 10³</td>
<td>8</td>
<td>850</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>L434</td>
<td>A 1,2 7.27, B I 3.0</td>
<td>NA NA &gt; 129 - 3.7 7.4 x 10³</td>
<td>8</td>
<td>630</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>L008</td>
<td>A 1,2 27.44, B II NA NA &gt; 140 - 4.5 NT</td>
<td>97</td>
<td>490</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>L157</td>
<td>A 1,2 13.14, B II NA NA &gt; 139 - 5.0 NT</td>
<td>88</td>
<td>710</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P493</td>
<td>A 1,2 8.38, B I 3.0</td>
<td>40 28 - 3.1 4.7 x 10³</td>
<td>5</td>
<td>420</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P1215</td>
<td>A 1,2 7.8, B I 3.0</td>
<td>72 50 - 4.4 3.2 x 10³</td>
<td>21</td>
<td>310</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P356</td>
<td>A 1,2 27.38, B I 3.0</td>
<td>41 38 - 7 1.9 x 10³</td>
<td>13</td>
<td>420</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P424</td>
<td>A 1,2 8.61, B I 10.6</td>
<td>43 46 - 14 4.0 x 10³</td>
<td>15</td>
<td>510</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P039</td>
<td>A 1,2 8.44, B I 3.4</td>
<td>39 39 - 19 7.4 x 10³</td>
<td>4</td>
<td>870</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* L, LTA; P, progressor. The number following L or P indicates the number of the participant in the Amsterdam Cohort studies on AIDS.
† I, seronegative; II, seropositive. Seroconversion interval is time between last seronegative and first seropositive visit.
‡ First time-point at which CD4⁺ T cell count was below 200 cells/µl.
§ Mean serum viral RNA load in first year after seroconversion.
NA, Not applicable.
NT, Not tested.

study entry (L211, L008 and L157). The other five individuals developed AIDS within 3–6 years (median 47 months, range 39–72) after seroconversion (P493, P1215, P356, P424 and P039). In accordance with our previous studies (Van Baalen et al., 1993, 1996; Klein & Miedema, 1995; Klein et al., 1995), and to highlight the profound difference in progression rates, these individuals are referred to as LTA and progressors, respectively. AIDS-defining symptoms of the progressors were: Kaposi’s sarcoma (P493); Candida albicans oesophagitis (P1215, P424 and P039); Pneumocystis carinii pneumonia (P356). Rates of CD4⁺ T cell decline (slopes) were calculated from CD4⁺ T cell counts measured at regular 3 monthly intervals during the entire follow-up period (Table 1). Only two of the twelve individuals received antiviral therapy during follow-up. For L008 and P1215 AZT therapy was started at 109 and 51 months after entry, respectively, and DDC therapy was started at 126 and 69 months, respectively. No CTLp frequencies were determined after the start of antiviral therapy. HLA-A and -B phenotypes of the individuals were serologically determined at the Department of Transplantation Immunology, CLB, Amsterdam (Table 1). Because CTL responses may be impaired as a result of disease progression, we decided to test samples collected before deterioration of the immune status had become evident. Retrospective CTLp frequency analyses were performed on the earliest available PBMC samples. Most of the individuals could also be tested during follow-up. The PBMC were cultured in vitro in RPMI 1640 containing 10% human pooled serum and recombinant IL-2 under limiting dilution conditions for 14–20 days, as described previously (Van Baalen et al., 1993; Klein et al., 1995). On day 0 and day 7, cultures were stimulated by addition of paraformaldehyde-fixed autologous serum and recombinant IL-2 under limiting dilution conditions for 14–20 days, as described previously (Van Baalen et al., 1993; Klein et al., 1995). On day 0 and day 7, cultures were stimulated by addition of paraformaldehyde-fixed autologous B lymphoblastoid cell lines infected with recombinant vaccinia viruses VVTG1144 (Gag), VVTG4163 (RT), VVTG1147 (Nef), VVTG4113 (Rev) or VVTG3196 (Tat), kindly provided by M. P. Kieny (Transgène, Strasbourg, France). Cytotoxic activity was measured by standard 4 h ³¹Cr-release assays (Van Baalen et al., 1993; Klein et al., 1995). CTLp frequency calculations were performed as described previously (Geretti et al., 1996).

The most striking finding of these studies was that Rev- and Tat-specific CTLp were predominantly detected in the LTA (Fig. 1): their frequencies in LTA and progressors proved to be
significantly different (Mann–Whitney $P < 0.01$ and $P < 0.05$, respectively). In contrast, CTLp directed against Gag, RT or Nef were found at similar frequencies in individuals of both groups.

Since all the progressors and four of the seven LTA were seronegative at study entry, the data could be analysed in relation to the time elapsed after infection. During the first 24 months after seroconversion, Rev-specific CTLp, but not Gag-, RT- or Nef-specific CTLp, proved to be significantly more prevalent in these LTA (Mann–Whitney $P < 0.02$). Due to limited numbers of PBMC, this analysis could not be made for Tat-specific CTLp. Collectively, these data show that the detection of Rev-specific CTLp early in the asymptomatic stage, as well as the detection of Rev- and Tat-specific CTLp during follow-up, are inversely correlated with rapid disease progression.

The failure to detect responses against Rev and Tat in the progressors could have resulted from an overall decline in CTLp frequencies or from the early impairment of CD4+ T cell function. However, as for the LTA, frequencies of CTLp against Gag, RT and Nef remained stable or even increased early after infection. This indicates that the absence of detectable Rev- and Tat-specific CTL activity in progressors was not due to a general failure of CTL responses in vivo.

To explain the specific absence of detectable Rev- and Tat-specific CTL responses in the progressors, a number of hypotheses may be considered. These include the absence of functional HLA–epitope complexes due to either host genetic (Klein et al., 1994; Kaslow et al., 1996) or viral characteristics (Phillips et al., 1991; Couillin et al., 1994; Koenig et al., 1995), and the mobilization of a restricted T-cell receptor repertoire (Pantaleo et al., 1994; Kalams et al., 1996). It may be expected...
on the basis of protein size that the number of CTL epitopes on Rev and Tat is smaller than that on Gag and RT. This may also explain the overall lower levels of CTLp against Rev and Tat in the LTA as compared to those against Gag, RT and Nef.

Given the number of matching HLA class I alleles between progressors and LTA, it may be considered that variation in viral sequences has had an impact on the generation of HLA–epitope complexes in these individuals. In support of this hypothesis, we found differences in the Rev sequences of viruses obtained from LTA L658 and progressor P424, who differed markedly in their CTL response to Rev but were identical for the HLA class I and class II alleles tested (Table 2).

<table>
<thead>
<tr>
<th>HLA-A1 (X[HST]XXXXXY)</th>
<th>HLA-A2 (X[LM]XXXXX[VLL])</th>
<th>HLA-B8(XX[KR]X[XK][XL])</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sequence</td>
<td>Frequency</td>
<td>Sequence</td>
</tr>
<tr>
<td>Lai</td>
<td>S...E...</td>
<td>YLGR...AEPY</td>
</tr>
<tr>
<td>L658</td>
<td>L,W...G...</td>
<td>16/20</td>
</tr>
<tr>
<td>L658</td>
<td>L,W...G...</td>
<td>16/20</td>
</tr>
<tr>
<td>L658</td>
<td>L,W...G...</td>
<td>16/20</td>
</tr>
<tr>
<td>P424</td>
<td>S...G...TS</td>
<td>15/19</td>
</tr>
<tr>
<td>P424</td>
<td>S...G...NS</td>
<td>4/19</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

explain the observed differences in CTL responses between LTA and progressors. Three of the seven LTA, but none of the progressors, were positive for HLA-B57. This allele has been suggested to be associated with prolonged survival (Klein et al., 1994; Kaslow et al., 1996). To address this point, a larger number of HLA-matched individuals would have to be studied. Whether Rev and Tat epitopes may be presented in the context of HLA-B57 is presently being studied.

To investigate the relationship between viral loads and disease progression rates in these individuals, serum viral RNA loads were determined in the individuals with a known seroconversion time-point (Table 1). Mean HIV-1 RNA loads in the first year after infection were quantified using a nucleic acid sequence-based amplification assay (NASBA HIV-1 RNA QT; Organon Teknika), according to the manufacturer’s instructions. As expected, these mean viral loads were relatively low in most LTA and high in the progressors. These differences could be due to viral characteristics. However, the *in vitro* replication of viruses isolated early after infection from these groups showed similar kinetics (H. Schuitemaker and others, unpublished), which is in line with the observation that predominantly slowly replicating NSI variants are transmitted (Connor & Ho, 1994).

Rev- and Tat-specific CTL may influence viral load more efficiently than CTL against structural proteins in different ways. Firstly, in the asymptomatic stage, many infected cells, both in circulation and in lymph nodes, do not actively produce virus, but do express multiple spliced mRNAs that encode the regulatory proteins (Seshamma et al., 1992; Embretson et al., 1993). This renders these cells targets for CTL against regulatory, but not against structural proteins. Secondly, in the replicative cycle, Rev and Tat are expressed earlier than the structural proteins. This may allow specific CTL to kill infected cells well before release of progeny virus (Ranki et al., 1994; Riviere et al., 1994). Although both considerations would also hold true for Nef, specific CTL responses to this protein were observed in most progressors. This may be
related to a lack of major structural constraints on Nef (Couillin et al., 1994; Koenig et al., 1995).

Our data which indicate that Rev- and Tat-specific CTL are involved in protection from rapid disease progression are in line with earlier suggestions that CTL responses against conserved and early proteins of HIV-1 would be protective (Johnson & Walker, 1994; Riviere et al., 1994, 1995; Harrer et al., 1996; Van Baalen et al., 1996). Recent data obtained from studies in SIVmac-infected macaques (Hulskotte et al., 1995) indicate that in these animals also, Rev-specific CTL responses inversely correlate with disease progression (A. M. Geretti, unpublished). Analysis of the efficacy of CTL specific for the early and regulatory proteins Rev and Tat in containing HIV-1 infection in in vitro and in vivo models, which are prompted by the results of the present study, will contribute to our understanding of the pathogenesis of human and animal lentivirus infections. This will facilitate the development of rational strategies for vaccination and specific immunotherapy.

We are indebted to the HIV-1-infected individuals who participate in the Amsterdam Cohort studies on AIDS, a collaboration between the Municipal Health Service, the Academic Medical Centre and the Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands. We acknowledge Marco van de Bildt and Patrick Boers for help with the sequencing, Francois Mallet for oligonucleotides, and Alewijn Ott (Department of Epidemiology & Biostatistics, Erasmus University, Rotterdam, The Netherlands) for advice on statistics. We thank Dr H Schuitemaker from the Department of Clinical Viro-Immunology of The Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands, for sharing unpublished results. We thank Conny Kruyssen for assistance in preparing the manuscript.

This study was supported by the Netherlands Foundation for Preventive Medicine and the Dutch AIDS foundation (grant 94038). RNA load determination and sampling was financially supported by the Netherlands Foundation for Preventive Medicine (grant 94019 and Basic Support Fund 282370).

References


Received 6 March 1997; Accepted 5 May 1997